Data from Global RACT Analysis Reveals Subjectivity
What are the most common risks in clinical trials? What challenges faces TransCelerate RACT? Read the answers in the latest article published on ACT. by Moe Alsumidaie, Beat Widler, PhD, Peter Schiemann, PhD, Artem Andrianov, PhD Do [...]
Clinical Trials: Viva Bias
by Alexandra Grossman Alexander K. is a thoughtful man, mid-50s, a writer by profession. He earns money with German and English lessons, and it is almost always tight. "A few years ago, I was sitting [...]
GCP Change – New Risks for Biotech?
Going Public Biotechnology Magazine p.76-77 The new upcoming GCP E6(R2) addendum reforms clinical monitoring and clinical trial management. Risk factors are an important component. What this means for a biotech company: clinical trial risks are [...]
Quality Risk Management as a Survival Kit
From Idea to Implementation (by Randy Ramin-Wright and Artem Andrianov) DIA Global Forum: Efficient risk management becomes more than advice today, it becomes part of a survival kit for a modern pharmaceutical company. Due to [...]
